High-dose intravenous methylprednisolone pulse therapy as initial treatment in cryptogenic fibrosing alveolitis. A pilot study.
Ten patients with fibrosing alveolitis were treated in a simple random design initially with either a high dose of methylprednisolone (5 patients) or a conventional dose of prednisolone (5 patients) followed by a maintenance dose of 30 mg prednisolone daily. The patients were followed for 6 weeks. No significant (p greater than 0.05) differences were observed between patients with high and low initial dose of glucocorticosteroids, as regards forced vital capacity, transfer factor for carbon monoxide or symptom scores after 3 and 6 weeks of treatment. After 6 weeks the dyspnoea score and the 67Ga uptake decreased, on average, by 74 and 85%, respectively, while forced vital capacity and transfer factor increased by 15 and 29%.
D000328:Adult; D000368:Aged; D002248:Carbon Monoxide; D004334:Drug Administration Schedule; D005260:Female; D005710:Gallium Radioisotopes; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D010865:Pilot Projects; D011653:Pulmonary Diffusing Capacity; D011658:Pulmonary Fibrosis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011877:Radionuclide Imaging; D011897:Random Allocation; D012129:Respiratory Function Tests
D005710:Gallium Radioisotopes; D002248:Carbon Monoxide; D008775:Methylprednisolone